ArriVent Biopharma has filed with the U.S. Securities and Exchange Commission to raise $175,000,000.00 in an Initial Public Offering

ArriVent Biopharma has filed with the U.S. Securities and Exchange Commission to raise $175,000,000.00 in an Initial Public Offering

According to filings with the U.S. Securities and Exchange Commission, ArriVent Biopharma is raising $175,000,000.00 in new funding. About ArriVent Biopharma: ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.

To learn more about ArriVent Biopharma, visit http://arrivent.com/

Contact:
Zhengbin Yao, Chief Executive Officer
628-277-4836
https://www.linkedin.com/in/zhengbin-bing-yao-4340b96/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.

Comments are closed.